

ring water soluble, Conjugated Estrogens equivalent in biological activity to 1.25 Mg. of Sodium Estrone Sulfate."

**RESULTS OF INVESTIGATION:** The tablets were shipped in interstate commerce in bulk drums under an invoice reading, in part, as follows: "Conjugated Estrogens 1.25 Mg. S. C. yellow oval. Each tablet contains: Naturally occurring water-soluble, conjugated forms of the mixed estrogens obtained from the urine of pregnant mares. The principal estrogen present is Sodium Estrone Sulfate with varying small amounts of other equine estrogens and relatively large quantities of Nonestrogenic material."

Upon receipt of the drums, the consignee repackaged the tablets into bottles labeled as described above. Analysis showed that the total estrogen content per tablet was equivalent to not more than 0.92 mg. of sodium estrone sulfate.

**LIBELED:** 8-27-56, N. Dist. Ala.

**CHARGE:** 501 (c)—the strength of the article, when shipped and while held for sale, differed from that which it purported and was represented to possess, namely, an amount of estrogens in each tablet equivalent to 1.25 mg. of sodium estrone sulfate; and 502 (a)—while held for sale, the label statement "Each Sugar-Coated Brown Tablet Contains: Naturally-occurring water soluble, Conjugated Estrogens equivalent in biological activity to 1.25 Mg. of Sodium Estrone Sulfate" was false and misleading.

**DISPOSITION:** 9-27-56. Default—destruction.

**5175. Orapin tablets.** (F. D. C. No. 39282. S. Nos. 38-883/5 M.)

**QUANTITY:** 1 23,000-tablet btl., 109 100-tablet btl., and 6 500-tablet btl. at Sarasota, Fla., in possession of Still Co., Inc., t/a Stillco Laboratories.

**SHIPPED:** 2-25-55, from Brooklyn, N. Y.

**LABEL IN PART:** (Btl.) "No. 154 Orapin 0.300 mgm. Conjugated Estrogens," "No. 148 Orapin 0.625 mgm. Conjugated Estrogens," or "No. 146 Orapin 1.25 mgm. Conjugated Estrogens."

**RESULTS OF INVESTIGATION:** Analyses showed that the tablets contained conjugated estrogens equivalent to (No. 154) 0.21 mg., (No. 148) 0.39 mg., and (No. 146) 0.78 mg. of sodium estrone sulfate per tablet.

**LIBELED:** 7-2-56, S. Dist. Fla.

**CHARGE:** 501 (c)—the strength of the tablets, while held for sale, differed from that which they purported and were represented to possess; and 502 (a)—the label statements (No. 154) "Each tablet contains conjugated estrogens equivalent to 0.300 mgm. of Sodium Estrone Sulphate," (No. 148) "Each tablet contains conjugated estrogens equivalent to 0.625 mgm. of Sodium Estrone Sulphate," and (No. 146) "Each tablet contains conjugated estrogens equivalent to 1.25 mgm. of Sodium Estrone Sulphate" were false and misleading.

**DISPOSITION:** 9-20-56. Default—destruction.

**5176. Adhesive bandages.** (F. D. C. No. 39411. S. No. 28-701 M.)

**QUANTITY:** 2 ctns., each containing 49 boxes, at San Francisco, Calif.

**SHIPPED:** 12-28-55, from Buffalo, N. Y., by United States Plastic Bandage Co.

**LABEL IN PART:** (Box) "Contains 100 Bandages  $\frac{3}{4}$ " x 3" Elast Aids Pliable Plastic Bandages \* \* \* Sterility guaranteed—unless envelope opened."